Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every quarter.
A routine blood test is about to sit at the center of a new US telehealth service, and the pitch is that your blood knows your age better than you do. Hong Kong-listed Regent Pacific Group says its subsidiary Deep Longevity will launch Accrua in the United States in October 2026, available to consumers in all 50 states [1].
The platform provides medical care online, led by licensed US clinicians. At its heart is Deep Longevity’s BloodAge report, which uses an AI model and a routine blood test to indicate whether someone is a “faster ager,” meaning their biological age is advancing more quickly than their calendar age.
After a consultation, users can get doctor-guided access to treatments in several categories: weight-loss medications such as GLP-1 therapies, peptides, women’s health treatments such as hormone replacement therapy, and men’s health treatments such as testosterone.
The company says each plan is personalized by a clinician and anchored to the BloodAge report, rather than to symptoms or a single biomarker, and BloodAge is re-measured every quarter so progress can be tracked. It all rolls up into what the company calls an integrated longevity care program, including compounded therapies.
According to the release, it’s the first time Deep Longevity’s aging-clock technology and SenoClock platform have reached consumers directly. Until now, the group has sold to clinics, hospitals, laboratories and insurers.
The science behind the score
The company points to a peer-reviewed study (Goshen et al, Aging and Disease, 2026) that followed roughly 2,600 adults for an average of 9.2 years. It found that each additional year of gap between biological and chronological age was associated with a 15% increase in mortality risk. Deep Longevity was also named runner-up in the Nestlé VITAL Smart Aging Global Challenge, which drew entries from 150 companies.
That finding is about prediction, and a useful one if it holds up. It tells you that people with older-looking blood tend to face higher risk. It doesn’t, by itself, show that choosing a treatment based on the score leads to better outcomes, and the release doesn’t present data on that. It’s the central open question for a service built on exactly that idea.
Regent Pacific itself is a Hong Kong investment group holding stakes across healthcare, wellness and life sciences, and says it has returned approximately US$298 million to shareholders since its May 1997 IPO. Deep Longevity, for its part, says its clock technology measures biological and cognitive aging across multiple physiological systems. The board describes Accrua as a significant new source of future revenue and a second growth curve.
A business case with a big comparison
The commercial logic is laid out plainly. The company adds that there’s no assurance Accrua will achieve comparable results, and a footnote says its revenues, if any, remain uncertain.
Accrua is built to be asset-light. Clinical delivery runs through established US telehealth infrastructure partners and a network of independent licensed physicians and pharmacy and compounding partners, so Deep Longevity doesn’t own clinical infrastructure or carry drug inventory. Revenue is expected to be mostly subscription-based. The platform is HIPAA-compliant and, the company says, will be LegitScript certified ahead of launch, with marketing initially focused on selected US states.
Jamie Gibson, Executive Director and CEO of Regent Pacific, called the launch “a landmark moment for Deep Longevity and for the Group.”
“We believe anchoring treatment to biological age – rather than to symptoms alone – is a genuinely new proposition in a market that has already demonstrated exceptional consumer demand,” he said.
Where it fits in longevity
Biological age tests have mostly lived in the world of curiosity and clinics. Putting one at the gate of prescriptions is a different use, and it will invite a few reasonable questions. How well does the score track real health in an individual, as opposed to a population? What happens when quarterly numbers wobble? And does the clinician’s judgment lead, or the report? Accrua’s launch gives the field a real-world test of whether aging clocks can move from research tools to everyday medical decision-making. The evidence for that step will have to come after launch.